drugset / Trial / NCT04500704
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
Phase 3
Unknown
166 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jiangsu Hansoh Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, controlled, phase III study.
Timeline
- Start
- 2020-10
- Primary completion
- 2021-12
- Completion
- 2023-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Almonertinib | Small molecule | 110 mg | Oral |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |